Gamma Knife radiosurgery for the treatment of Nelson's syndrome: a multicenter, international study.

ACTH ACTH = adrenocorticotrophic hormone BA = bilateral adrenalectomy CD = Cushing’s disease CN = cranial nerve CS = cavernous sinus Cushing’s disease DI = diabetes insipidus FSH = follicle-stimulating hormone GH = growth hormone GKRS GKRS = Gamma Knife radiosurgery Gamma Knife radiosurgery IGF-1 = insulin-like growth factor–1 IRRF = International Radiosurgery Research Foundation NS = Nelson’s syndrome Nelson’s syndrome OC = optic chiasm ON = optic nerve OT = optic tract RT = radiation therapy SRS SRS = stereotactic radiosurgery T4 = free thyroxin TSH = thyroid-stimulating hormone TSR = transsphenoidal resection adrenocorticotrophic hormone pituitary surgery stereotactic radiosurgery

Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
12 Jul 2019
Historique:
received: 27 02 2019
accepted: 19 04 2019
entrez: 13 7 2019
pubmed: 13 7 2019
medline: 13 7 2019
Statut: aheadofprint

Résumé

Nelson's syndrome is a rare and challenging neuroendocrine disorder, and it is associated with elevated adrenocorticotrophic hormone (ACTH) level, skin hyperpigmentation, and pituitary adenoma growth. Management options including resection and medical therapy are traditional approaches. Ionizing radiation in the form of Gamma Knife radiosurgery (GKRS) is also being utilized to treat Nelson's syndrome. In the current study the authors sought to better define the therapeutic role of stereotactic radiosurgery (SRS) in Nelson's syndrome. Study patients with Nelson's syndrome were treated with single-fraction GKRS (median margin dose of 25 Gy) at 6 different centers as part of an International Radiosurgery Research Foundation (IRRF) investigation. Data including neurological function, endocrine response, and radiological tumor response were collected and sent to the study-coordinating center for review. Fifty-one patients with median endocrine and radiological follow-ups of 91 and 80.5 months from GKRS, respectively, were analyzed for endocrine remission, tumor control, and neurological outcome. Statistical methods were used to identify prognostic factors for these endpoints. At last follow-up, radiological tumor control was achieved in 92.15% of patients. Endocrine remission off medical management and reduction in pre-SRS ACTH level were achieved in 29.4% and 62.7% of patients, respectively. Improved remission rates were associated with a shorter time interval between resection and GKRS (p = 0.039). Hypopituitarism was seen in 21.6% and new visual deficits were demonstrated in 15.7% of patients. GKRS affords a high rate of pituitary adenoma control and improvement in ACTH level for the majority of Nelson's syndrome patients. Hypopituitarism is the most common adverse effect from GKRS in Nelson's syndrome patients and warrants longitudinal follow-up for detection and endocrine replacement.

Identifiants

pubmed: 31299652
doi: 10.3171/2019.4.JNS19273
pii: 2019.4.JNS19273
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

1-6

Auteurs

Diogo Cordeiro (D)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Zhiyuan Xu (Z)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Chelsea E Li (CE)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Christian Iorio-Morin (C)

2Department of Surgery, Division of Neurosurgery, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada.

David Mathieu (D)

2Department of Surgery, Division of Neurosurgery, Université de Sherbrooke, Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada.

Nathaniel D Sisterson (ND)

3Department of Neurological Surgery, University of Pittsburgh, Pennsylvania.

Hideyuki Kano (H)

3Department of Neurological Surgery, University of Pittsburgh, Pennsylvania.

Luca Attuati (L)

4Neurosurgery and Gamma Knife Radiosurgery, Humanitas Research Hospital, Rozzano, Milano, Italy.

Piero Picozzi (P)

4Neurosurgery and Gamma Knife Radiosurgery, Humanitas Research Hospital, Rozzano, Milano, Italy.

Kimball A Sheehan (KA)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Cheng-Chia Lee (CC)

5Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, People's Republic of China; and.

Roman Liscak (R)

6Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

Jana Jezkova (J)

6Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic.

L Dade Lunsford (LD)

3Department of Neurological Surgery, University of Pittsburgh, Pennsylvania.

Jason Sheehan (J)

1Department of Neurological Surgery, University of Virginia Health System, Charlottesville, Virginia.

Classifications MeSH